Palisade Bio, Inc. (NASDAQ:PALI – Get Free Report) Director Robert Jr. Baltera bought 30,000 shares of the business’s stock in a transaction on Tuesday, July 7th. The shares were acquired at an average price of $2.03 per share, with a total value of $60,900.00. Following the transaction, the director owned 416,904 shares of the company’s stock, valued at $846,315.12. The trade was a 7.75% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
Robert Jr. Baltera also recently made the following trade(s):
- On Monday, July 6th, Robert Jr. Baltera purchased 20,000 shares of Palisade Bio stock. The stock was acquired at an average price of $2.05 per share, for a total transaction of $41,000.00.
- On Thursday, July 2nd, Robert Jr. Baltera acquired 10,000 shares of Palisade Bio stock. The shares were bought at an average price of $1.98 per share, with a total value of $19,800.00.
- On Wednesday, July 1st, Robert Jr. Baltera bought 20,000 shares of Palisade Bio stock. The stock was bought at an average cost of $1.98 per share, for a total transaction of $39,600.00.
Palisade Bio Price Performance
Palisade Bio stock traded down $0.03 during mid-day trading on Wednesday, hitting $2.05. 3,270,900 shares of the company were exchanged, compared to its average volume of 4,120,142. The business’s 50 day simple moving average is $1.91 and its two-hundred day simple moving average is $1.92. The company has a market capitalization of $355.84 million, a P/E ratio of -2.03 and a beta of 1.50. Palisade Bio, Inc. has a 12-month low of $0.53 and a 12-month high of $2.86.
Hedge Funds Weigh In On Palisade Bio
A number of large investors have recently modified their holdings of PALI. Cetera Investment Advisers acquired a new position in shares of Palisade Bio in the 4th quarter valued at about $25,000. Schonfeld Strategic Advisors LLC purchased a new position in Palisade Bio in the fourth quarter valued at approximately $26,000. Virtu Financial LLC acquired a new position in Palisade Bio during the fourth quarter valued at approximately $28,000. CTC Alternative Strategies Ltd. purchased a new stake in Palisade Bio during the first quarter worth approximately $31,000. Finally, Atom Investors LP acquired a new stake in shares of Palisade Bio in the fourth quarter worth $33,000. 11.79% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
Several equities research analysts have issued reports on the stock. Wolfe Research assumed coverage on shares of Palisade Bio in a research note on Thursday, April 9th. They set an “outperform” rating and a $7.00 price target on the stock. Wall Street Zen upgraded shares of Palisade Bio from a “sell” rating to a “hold” rating in a research report on Sunday. LADENBURG THALM/SH SH upgraded Palisade Bio to a “strong-buy” rating in a report on Thursday, June 25th. Oppenheimer set a $7.00 price objective on Palisade Bio in a report on Tuesday, June 30th. Finally, HC Wainwright reiterated a “buy” rating and issued a $2.00 target price on shares of Palisade Bio in a research note on Tuesday, June 30th. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $8.83.
View Our Latest Report on Palisade Bio
About Palisade Bio
Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.
The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.
Featured Articles
- Five stocks we like better than Palisade Bio
- A Market Panic Just Discounted the AI Highway’s Tollbooth
- Why Exxon Could Be the Market’s Next Big Comeback Stock
- The Market Just Got Shaken—These 3 ETFs May Come Out Stronger
- Meta Platforms’ Cloud Push: Growth Opportunity Versus AI Concerns
Receive News & Ratings for Palisade Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palisade Bio and related companies with MarketBeat.com's FREE daily email newsletter.
